208 related articles for article (PubMed ID: 38630656)
1. Recent Progress of Small Interfering RNA Delivery on the Market and Clinical Stage.
Guo F; Li Y; Yu W; Fu Y; Zhang J; Cao H
Mol Pharm; 2024 May; 21(5):2081-2096. PubMed ID: 38630656
[TBL] [Abstract][Full Text] [Related]
2. Pre-Clinical and Clinical Applications of Small Interfering RNAs (siRNA) and Co-Delivery Systems for Pancreatic Cancer Therapy.
Mirzaei S; Gholami MH; Ang HL; Hashemi F; Zarrabi A; Zabolian A; Hushmandi K; Delfi M; Khan H; Ashrafizadeh M; Sethi G; Kumar AP
Cells; 2021 Nov; 10(12):. PubMed ID: 34943856
[TBL] [Abstract][Full Text] [Related]
3. Where should siRNAs go: applicable organs for siRNA drugs.
Ahn I; Kang CS; Han J
Exp Mol Med; 2023 Jul; 55(7):1283-1292. PubMed ID: 37430086
[TBL] [Abstract][Full Text] [Related]
4. Nanoparticle Delivery Platforms for RNAi Therapeutics Targeting COVID-19 Disease in the Respiratory Tract.
Zhang Y; Almazi JG; Ong HX; Johansen MD; Ledger S; Traini D; Hansbro PM; Kelleher AD; Ahlenstiel CL
Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269550
[TBL] [Abstract][Full Text] [Related]
5. Nanoparticle-based delivery system for application of siRNA in vivo.
Wang Y; Li Z; Han Y; Liang LH; Ji A
Curr Drug Metab; 2010 Feb; 11(2):182-96. PubMed ID: 20359287
[TBL] [Abstract][Full Text] [Related]
6. Recent advances in siRNA delivery.
Sarisozen C; Salzano G; Torchilin VP
Biomol Concepts; 2015 Dec; 6(5-6):321-41. PubMed ID: 26609865
[TBL] [Abstract][Full Text] [Related]
7. The cutting-edge technologies of siRNA delivery and their application in clinical trials.
Lee K; Jang B; Lee YR; Suh EY; Yoo JS; Lee MJ; Lee JY; Lee H
Arch Pharm Res; 2018 Sep; 41(9):867-874. PubMed ID: 30136248
[TBL] [Abstract][Full Text] [Related]
8. Lipid nanoparticles for short interfering RNA delivery.
Leung AK; Tam YY; Cullis PR
Adv Genet; 2014; 88():71-110. PubMed ID: 25409604
[TBL] [Abstract][Full Text] [Related]
9. siRNA delivery systems for cancer treatment.
Oh YK; Park TG
Adv Drug Deliv Rev; 2009 Aug; 61(10):850-62. PubMed ID: 19422869
[TBL] [Abstract][Full Text] [Related]
10. Delivery systems and local administration routes for therapeutic siRNA.
Vicentini FT; Borgheti-Cardoso LN; Depieri LV; de Macedo Mano D; Abelha TF; Petrilli R; Bentley MV
Pharm Res; 2013 Apr; 30(4):915-31. PubMed ID: 23344907
[TBL] [Abstract][Full Text] [Related]
11. [Advance in the study of targeting delivery system for siRNA mediated by aptamers].
Wang XL; Wang QQ; Song HF
Yao Xue Xue Bao; 2012 Jul; 47(7):850-5. PubMed ID: 22993847
[TBL] [Abstract][Full Text] [Related]
12. Nanovehicle-based Small Interfering RNA (siRNA) Delivery for Therapeutic Purposes: A New Molecular Approach in Pharmacogenomics.
Akhtari J; Tafazoli A; Mehrad-Majd H; Mahrooz A
Curr Clin Pharmacol; 2018; 13(3):173-182. PubMed ID: 29992895
[TBL] [Abstract][Full Text] [Related]
13. Strategies, design, and chemistry in siRNA delivery systems.
Dong Y; Siegwart DJ; Anderson DG
Adv Drug Deliv Rev; 2019 Apr; 144():133-147. PubMed ID: 31102606
[TBL] [Abstract][Full Text] [Related]
14. Small interfering RNAs (siRNAs) in cancer therapy: a nano-based approach.
Mahmoodi Chalbatani G; Dana H; Gharagouzloo E; Grijalvo S; Eritja R; Logsdon CD; Memari F; Miri SR; Rad MR; Marmari V
Int J Nanomedicine; 2019; 14():3111-3128. PubMed ID: 31118626
[TBL] [Abstract][Full Text] [Related]
15. Recent progress in development of siRNA delivery vehicles for cancer therapy.
Kim HJ; Kim A; Miyata K; Kataoka K
Adv Drug Deliv Rev; 2016 Sep; 104():61-77. PubMed ID: 27352638
[TBL] [Abstract][Full Text] [Related]
16. Polyethylenimines for RNAi-mediated gene targeting in vivo and siRNA delivery to the lung.
Günther M; Lipka J; Malek A; Gutsch D; Kreyling W; Aigner A
Eur J Pharm Biopharm; 2011 Apr; 77(3):438-49. PubMed ID: 21093588
[TBL] [Abstract][Full Text] [Related]
17. The growth of siRNA-based therapeutics: Updated clinical studies.
Zhang MM; Bahal R; Rasmussen TP; Manautou JE; Zhong XB
Biochem Pharmacol; 2021 Jul; 189():114432. PubMed ID: 33513339
[TBL] [Abstract][Full Text] [Related]
18. Lysosomal Storage Disease-Associated Neuropathy: Targeting Stable Nucleic Acid Lipid Particle (SNALP)-Formulated siRNAs to the Brain as a Therapeutic Approach.
Coutinho MF; Santos JI; S Mendonça L; Matos L; Prata MJ; S Jurado A; Pedroso de Lima MC; Alves S
Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32785133
[TBL] [Abstract][Full Text] [Related]
19. Molecular design and delivery of siRNA.
Inoue A; Sawata SY; Taira K
J Drug Target; 2006; 14(7):448-55. PubMed ID: 17062391
[TBL] [Abstract][Full Text] [Related]
20. Delivering siRNA with Dendrimers: In Vivo Applications.
Leiro V; Santos SD; Pego AP
Curr Gene Ther; 2017; 17(2):105-119. PubMed ID: 28494741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
